Showing 1 - 6 results of 6 for search 'David F McDermott', query time: 0.02s Refine Results
  1. 1
    Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial

    Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial by Xiaomin He, Emiliano Calvo, David F McDermott, Valentina Boni, Olivier Dumas, Arvind Chaudhry, Sang Joon Shin, Seth D Rosen, Philip R Debruyne, Ulka N Vaishampayan

    Published 2025-08-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Soluble PD-L1 as an early marker of progressive disease on nivolumab

    Soluble PD-L1 as an early marker of progressive disease on nivolumab by David F McDermott, Gordon J Freeman, Toni K Choueiri, Petra Ross-MacDonald, F Stephen Hodi, Megan Wind-Rotolo, Long Yuan, Kathleen M Mahoney, Linan Song, Eliseo Veras

    Published 2022-02-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Role of high-dose interleukin-2 for melanoma in the age of cellular therapy

    Role of high-dose interleukin-2 for melanoma in the age of cellular therapy by Mario Sznol, Elizabeth Buchbinder, Rodabe Amaria, Amod Sarnaik, David F McDermott, Michael B Atkins, Ann W Silk, Kim A Margolin, Michael T Lotze, Zeynep Eroglu, Virginia Seery, Allison Betof Warner, Harriet M Kluger, Karam Khaddour

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma

    Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma by Jin Yao, Thomas Powles, David F McDermott, Toni K Choueiri, Petra Ross-MacDonald, Simon Papillon-Cavanagh, Robert J Motzer, M Brent McHenry, Megan Wind-Rotolo, Ron Ammar, Yann-Alexandre Vano, Saurabh Gupta, Celine Han, Shruti S Saggi

    Published 2022-03-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

    Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A) by Michael Hurwitz, Mark Stein, Jeffrey Sosman, David F McDermott, Michael B Atkins, Naomi B Haas, Elizabeth R Plimack, Hans Hammers, Mehmet A Bilen, Meredith M Regan, Moshe C Ornstein, David Einstein, Opeyemi A Jegede, Robert Alter, David J Peace, Paul J Catalano

    Published 2024-04-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)

    Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1) by Lucy Gilbert, Jameel Muzaffar, Vamsidhar Velcheti, Anna Spreafico, Emiliano Calvo, David F McDermott, Marc S Ernstoff, Valentina Boni, Karl D Lewis, Ira Winer, Olivier Dumas, Aman Chauhan, Arvind Chaudhry, Christoper J Hoimes, Seth D Rosen, Debora S Bruno, James F Strauss, Rita Dalal, Ulka N Vaishampayan, Quincy S Chu

    Published 2024-11-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: